[Effect of miR-342-3p on chemotherapy sensitivity in triple-negative breast cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to limited targeted therapies.
• MicroRNAs (miRNAs) are emerging as critical regulators in cancer progression and treatment response.
• Understanding the role of specific miRNAs, like miR-342-3p, is crucial for developing novel therapeutic strategies for TNBC.

Purpose of the Study:

• To investigate the impact of miR-342-3p expression on the sensitivity of triple-negative breast cancer (TNBC) to chemotherapy.
• To explore the potential of miR-342-3p as a predictive biomarker for chemotherapy response in TNBC patients.

Main Methods:

• Retrospective analysis of miR-342-3p expression in TNBC tissues from patients with varying chemotherapy responses (complete vs. partial response).
• In vitro studies using MDA-MB-231 breast cancer cell lines transfected with miR-342-3p mimics or inhibitors.
• Assessment of cell viability and apoptosis following treatment with paclitaxel, cisplatin, or doxorubicin in transfected cell lines.

Main Results:

• Higher miR-342-3p expression was observed in TNBC tissues from patients achieving complete response compared to partial response.
• Overexpression of miR-342-3p (mimic) significantly increased chemoresistance to paclitaxel and cisplatin, while its inhibition decreased sensitivity.
• miR-342-3p did not significantly affect the sensitivity of MDA-MB-231 cells to doxorubicin.

Conclusions:

• High miR-342-3p expression correlates with increased chemotherapy sensitivity in triple-negative breast cancer.
• miR-342-3p plays a role in modulating the response of TNBC cells to paclitaxel and cisplatin.
• miR-342-3p does not appear to influence doxorubicin sensitivity in TNBC cell lines, suggesting drug-specific regulatory mechanisms.